Prestige Consumer Healthcare Inc.

NYSE:PBH Stock Report

Market Cap: US$3.6b

Prestige Consumer Healthcare Future Growth

Future criteria checks 3/6

Prestige Consumer Healthcare is forecast to grow earnings and revenue by 34.5% and 2.1% per annum respectively. EPS is expected to grow by 34.8% per annum. Return on equity is forecast to be 10.8% in 3 years.

Key information

34.5%

Earnings growth rate

34.8%

EPS growth rate

Pharmaceuticals earnings growth21.4%
Revenue growth rate2.1%
Future return on equity10.8%
Analyst coverage

Good

Last updated08 Mar 2024

Recent future growth updates

Prestige Consumer Healthcare Inc. (NYSE:PBH) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

Feb 11
Prestige Consumer Healthcare Inc. (NYSE:PBH) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

Recent updates

Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly

Mar 26
Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly

An Intrinsic Calculation For Prestige Consumer Healthcare Inc. (NYSE:PBH) Suggests It's 50% Undervalued

Mar 05
An Intrinsic Calculation For Prestige Consumer Healthcare Inc. (NYSE:PBH) Suggests It's 50% Undervalued

Prestige Consumer Healthcare Inc. (NYSE:PBH) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

Feb 11
Prestige Consumer Healthcare Inc. (NYSE:PBH) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Shares May Have Run Too Fast Too Soon

Feb 05
Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Shares May Have Run Too Fast Too Soon

Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly

Dec 14
Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly

Prestige Consumer Healthcare (NYSE:PBH) Seems To Use Debt Quite Sensibly

Sep 10
Prestige Consumer Healthcare (NYSE:PBH) Seems To Use Debt Quite Sensibly

Prestige Consumer Healthcare: Unproductive Buyback And Excessive Valuation

Aug 15

Is Prestige Consumer Healthcare (NYSE:PBH) Using Too Much Debt?

Jun 12
Is Prestige Consumer Healthcare (NYSE:PBH) Using Too Much Debt?

An Intrinsic Calculation For Prestige Consumer Healthcare Inc. (NYSE:PBH) Suggests It's 43% Undervalued

May 20
An Intrinsic Calculation For Prestige Consumer Healthcare Inc. (NYSE:PBH) Suggests It's 43% Undervalued

Here's Why Prestige Consumer Healthcare (NYSE:PBH) Has Caught The Eye Of Investors

Mar 17
Here's Why Prestige Consumer Healthcare (NYSE:PBH) Has Caught The Eye Of Investors

Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly

Mar 02
Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly

Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Intrinsic Value Is Potentially 75% Above Its Share Price

Feb 08
Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Intrinsic Value Is Potentially 75% Above Its Share Price

Prestige Consumer Healthcare reports Q3 earnings beat; updates FY23 guidance

Feb 02

Prestige Consumer Healthcare: Taking My Winnings Off The Table

Jan 19

Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly

Nov 23
Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly

Prestige Consumer Healthcare GAAP EPS of $1.02 beats by $0.02, revenue of $289.3M beats by $6.07M

Nov 03

Holding Prestige Consumer Healthcare

Aug 31

If EPS Growth Is Important To You, Prestige Consumer Healthcare (NYSE:PBH) Presents An Opportunity

Aug 26
If EPS Growth Is Important To You, Prestige Consumer Healthcare (NYSE:PBH) Presents An Opportunity

We Think Prestige Consumer Healthcare (NYSE:PBH) Can Stay On Top Of Its Debt

Aug 05
We Think Prestige Consumer Healthcare (NYSE:PBH) Can Stay On Top Of Its Debt

Prestige Consumer Healthcare GAAP EPS of $1.09 beats by $0.05, revenue of $277.1M beats by $8.18M

Aug 04

Should You Be Adding Prestige Consumer Healthcare (NYSE:PBH) To Your Watchlist Today?

May 27
Should You Be Adding Prestige Consumer Healthcare (NYSE:PBH) To Your Watchlist Today?

Is Prestige Consumer Healthcare (NYSE:PBH) A Risky Investment?

May 05
Is Prestige Consumer Healthcare (NYSE:PBH) A Risky Investment?

Does Prestige Consumer Healthcare (NYSE:PBH) Deserve A Spot On Your Watchlist?

Feb 22
Does Prestige Consumer Healthcare (NYSE:PBH) Deserve A Spot On Your Watchlist?

Is Prestige Consumer Healthcare (NYSE:PBH) A Risky Investment?

Feb 03
Is Prestige Consumer Healthcare (NYSE:PBH) A Risky Investment?

These 4 Measures Indicate That Prestige Consumer Healthcare (NYSE:PBH) Is Using Debt Extensively

Nov 04
These 4 Measures Indicate That Prestige Consumer Healthcare (NYSE:PBH) Is Using Debt Extensively

Here's Why Prestige Consumer Healthcare (NYSE:PBH) Has A Meaningful Debt Burden

Aug 06
Here's Why Prestige Consumer Healthcare (NYSE:PBH) Has A Meaningful Debt Burden

Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Could Be 50% Below Their Intrinsic Value Estimate

Jun 14
Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Could Be 50% Below Their Intrinsic Value Estimate

Prestige Consumer Healthcare Inc. 2021 Q4 - Results - Earnings Call Presentation

May 08

These 4 Measures Indicate That Prestige Consumer Healthcare (NYSE:PBH) Is Using Debt Extensively

Apr 19
These 4 Measures Indicate That Prestige Consumer Healthcare (NYSE:PBH) Is Using Debt Extensively

How Much Did Prestige Consumer Healthcare's (NYSE:PBH) CEO Pocket Last Year?

Feb 22
How Much Did Prestige Consumer Healthcare's (NYSE:PBH) CEO Pocket Last Year?

Earnings and Revenue Growth Forecasts

NYSE:PBH - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/20261,1902392862874
3/31/20251,1622312722747
3/31/20241,1362172682647
12/31/20231,134-81232241N/A
9/30/20231,127-82216224N/A
6/30/20231,130-84211220N/A
3/31/20231,128-82222230N/A
12/31/20221,109210225234N/A
9/30/20221,108209236245N/A
6/30/20221,095203240249N/A
3/31/20221,087205250260N/A
12/31/20211,058189245256N/A
9/30/20211,022179224239N/A
6/30/2021983179209230N/A
3/31/2021943165213236N/A
12/31/2020957166207233N/A
9/30/2020960163218241N/A
6/30/2020960152222240N/A
3/31/2020963142203217N/A
12/31/2019953-34199212N/A
9/30/2019953-34186197N/A
6/30/2019954-36176186N/A
3/31/2019976-36179189N/A
12/31/201899164183193N/A
9/30/20181,020340184197N/A
6/30/20181,039340199212N/A
3/31/20181,041340198210N/A
12/31/20171,026390152163N/A
9/30/2017972107N/A156N/A
6/30/2017929109N/A151N/A
3/31/201788269N/A149N/A
12/31/201684972N/A179N/A
9/30/201683369N/A185N/A
6/30/201682468N/A182N/A
3/31/2016806100N/A176N/A
12/31/2015788110N/A189N/A
9/30/2015786103N/A190N/A
6/30/201576188N/A170N/A
3/31/201571578N/A156N/A
12/31/201466870N/A135N/A
9/30/201461552N/A113N/A
6/30/201460169N/A118N/A
3/31/201459773N/A112N/A
12/31/201360976N/A118N/A
9/30/201362485N/A133N/A
6/30/201361972N/A146N/A
3/31/201362066N/A138N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PBH is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: PBH is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: PBH is expected to become profitable in the next 3 years.

Revenue vs Market: PBH's revenue (2.1% per year) is forecast to grow slower than the US market (8.2% per year).

High Growth Revenue: PBH's revenue (2.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PBH's Return on Equity is forecast to be low in 3 years time (10.8%).


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.